FDA
FDA Articles
Portola Pharmaceuticals shares saw a handy gain on Tuesday after the company announced that it received a key approval from the FDA.
Published:
Last Updated:
Teva Pharmaceutical Industries kicked off the week by announced an FDA for its treatment for migraines.
Published:
Last Updated:
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
Published:
Last Updated:
A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a generic version of the pill?
Published:
Last Updated:
SteadyMed saw its shares make an incredibly gain to close out the week, after a positive meeting with the FDA.
Published:
Last Updated:
Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial.
Published:
Last Updated:
Otonomy reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease.
Published:
Last Updated:
Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the FDA.
Published:
Last Updated:
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
Published:
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Published:
Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some buzz for Gilead.
Published:
Last Updated:
24/7 Wall St. has collected a few more catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
Last Updated:
Rigel Pharmaceuticals has suffered over the past year, but it seems this update may be the catalyst it has been looking for.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Published:
Last Updated: